(Q43576010)

English

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

scientific article published in August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Jacob Atsmon

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Jasper Dingemanse

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimitri Shaikevich

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Inna Volokhov

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Patricia N Sidharta

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

1 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

685-692

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Endothelin system: the double-edged sword in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Endothelin: 20 years from discovery to therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Why are pharmacokinetic data summarized by arithmetic means?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0063-8

21 January 2018

Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23568224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23568224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/23568224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23568224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-013-0063-8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43576010&oldid=2206136900"